Formycon and its licensing partner Bioeq have celebrated receiving a positive opinion from the Committee for Medicinal Products for Human Use within the European Medicines Agency, recommending granting a pan-European marketing authorization for the firms’ FYB201 biosimilar rival to Lucentis (ranibizumab) under the name Ranivisio.
The positive opinion represents the second biosimilar version of Lucentis to be endorsed by the EMA, following Samsung Bioepis receiving...






